Resultado de búsqueda
ANT01 shows a unique combined high BLOCKING affinity toward the human serotonin 2A and dopamine 4 receptor. Imaging of the serotonergic 5-HT2A receptor system in the Human Brain, target of ANT01, and which is involved in brain disorders such as depression and Alzheimer’s Disease.
5 de jun. de 2023 · ANeuroTech receives IND approval from the FDA for pivotal Phase IIIB trial of adjunctive anti-depression drug, ANT-01 SOURCE: globenewswire.comJune 05, 2023 07:00 ET Alken, Belgium – 5 June 2023: ANeuroTech, a leader in the development of innovative mental health treatments with minimal or no side effects, today announces that the US Food and Drug Administration (FDA) has approved its ...
Market Opportunities. ANEUROTECH is developing its late stage Phase III drug ANT01 in Partial Responsive Depression (PRD). ANT01 is an once daily, orally-administered small molecule to attack Subjective Cognitive Decline and Potentiate Initial Antidepressant Therapies.
31 de ene. de 2024 · Alken, Belgium – 31 January 2024: ANeuroTech, a leader in the development of innovative mental health treatments with minimal or no side effects, today announced the publication of Phase IIIa ...
5 de jun. de 2023 · ANeuroTechreceives IND approval from the FDA for pivotal Phase IIIB trial of adjunctive anti-depression drug, ANT-01. ANT-01 in developmentas an adjunctive treatment forMajor Depressive Disorder (MDD), with minimal side effects; Phase IIIB trial to begin later this year in the US, Europe and South America; Company funding secured from international impact investing company, KOIS, as part of ...
5 de jun. de 2023 · ANeuroTech receives IND approval from the FDA for pivotal Phase IIIB trialof adjunctive anti-depression drug, ANT-01 ANT-01 in development as an adjunctive treatment for Major Depressive Disorder ...
6 de jun. de 2023 · Tuesday, June 06, 2023. ANeuroTech, a pioneering company in the field of mental health treatments with minimal or no side effects, has received approval from the US Food and Drug Administration (FDA) to begin a pivotal Phase IIIB trial of their drug, ANT-01. This trial will investigate the potential of ANT-01 as an adjunctive treatment for ...
